Skip to Content
Søg Menu
2023

Få seneste nyt fra EHA – Se MEDtalks og læs artikler

Seneste nyt fra EHA 2023

Overlevelsesgevinst for skrøbelige CLL-patienter i behandling med Imbruvica og Venclyxto

  • / Carsten Utoft Niemann

Anna Sureda Balari

Epcoritamab with rituximab and lenalidomide (R2) for patients with high-risk follicular lymphoma

/ Anna Sureda Balari
EHA23Lymfom Play the Video
Mark Levis

Gilteritinib for patients with newly diagnosed AML

/ Mark Levis
EHA23Ernæring Play the Video
Arnon Kater

MURANO study supports the use of fixed-duration VenR in R/R CLL

/ Arnon Kater
EHA23CLL Play the Video
Evangelos Terpos

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma

/ Evangelos Terpos
EHA23Myelomatose Play the Video
Ryan Jacobs

News from EHA23 – A promising treatment option for follicular lymphoma

/ Ryan Jacobs
EHA23Lymfom Play the Video
Barbara Eichhorst

What is new from EHA23 regarding treatment Strategies in First-Line CLL?

/ Barbara Eichhorst
EHA23CLL Play the Video
Eva Futtrup Maksten

Risk of dementia in older patients treated with chemotherapy for lymphoma

/ Eva Futtrup Maksten
EHA23LymfomDemens Play the Video

Belamaf and Dexamethasone – Safe, Effective Multiple Myeloma Treatment

/ Evangelos Terpos / Jan Andreasen
EHA23Myelomatose

Belamaf shows deeper, longer-lasting myeloma response

/ Jan Andreasen
EHA23Myelomatose
Hent flere

Onkologi/Hæmatologi • Nr. 10 • 2023

  • LAG3-hæmmere ændrer immunterapiens behandlingslandskab
  • Highlights fra ASCO GI & GU
  • Highlights fra ASH 2022
  • Myelomatose: Geografisk betinget? 
Get access

Højdepunkter fra EHA webinar 2022

Martin Hutchings

Hidtil højeste overall survival udfordrer 1.-linjebehandling ved Hodgkin lymfom

/ Martin Hutchings
Lymfom Play the Video
Martin Hutchings

To bispecifikke antistoffer er på vej mod godkendelse mod diffust storcellet B-celle lymfom

/ Martin Hutchings
Lymfom Play the Video
Carsten Utoft Niemann

Tidsbegrænset venetoclax-baseret kombinationsbehandling opnår bedre PFS og MRD-negativitet ved behandling af CLL

/ Carsten Utoft Niemann
CLL Play the Video
Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video

MEDtalks fra EHA 2022

AML

FLT3 Inhibitor Gilteritinib Shows Potential in Post-Transplant Maintenance for AML

/ Hæmatologi / Mark J. Levis

Treatment Options for FLT3 mutant acute myeloid leukemia

/ Hæmatologi / Eunice Wang

UK NCRI AML19 Trial – Liposomal daunorubicin and cytarabine had a significant survival benefit

/ Hæmatologi / Jad Othman

AML patients with FLT3-ITD and wild-type NPM1 has a significant improvement of LFS, OS and GRFS

/ Hæmatologi / Ali Bazarbachi

AML-highlights fra ASH22 – i dansk perspektiv

/ Hæmatologi / Hans Beier Ommen
Se oversigt

CLL

New Research from EHA23 Points to Similar Effectiveness of Acalabrutinib and Zanubrutinib in R/R CLL Treatment

/ Hæmatologi / Alan Z. Skarbnik

UK Trial Gives Voice to CLL Patients’ Experiences with Targeted Therapies

/ Hæmatologi / Dima El-Sharkawi

MURANO 7-års data viser fortsat effekt ved R/R CLL – men giver ikke svar på alle spørgsmål

/ Hæmatologi / Carsten Utoft Niemann

New CLL Study Supports Inclusion of Venetoclax Plus Obinutuzumab in Treatment Guidelines

/ Hæmatologi / Othman Al-sawaf

CLL14-studiet er tæt på overlevelsesgevinst for skrøbelige patienter med CLL

/ Hæmatologi / Carsten Utoft Niemann
Se oversigt

Lymfom

Therapeutic options for patients with primary refractory or early relapsed DLBCL

/ Hæmatologi / Manali Kamdar

Promising Findings for R/R Large B-cell Lymphoma – Glofitama and Epcoritamab Show Curative Potential

/ Hæmatologi / Martin Hutchings

Axicabtagene ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients

/ Hæmatologi / Roch Houot

Evidence to use MRD after induction therapy of AML

/ Hæmatologi / Jacqueline Cloos

R/R Large B-cell Lymphoma: Interesting results from ASH 2022 for treatment with Yescarta (axicabtagene ciloleucel)

/ Hæmatologi / Frederick L. Locke
Se oversigt

Myelomatose

CRTH award winning study demonstrates malignancy risks for CLL patients

/ Hæmatologi / Thomas Chatzikonstantinou

Acalabrutinib Shows Lower Cardiac Failure Rates Than Ibrutinib in CLL Treatment

/ Hæmatologi / Paolo Ghia

Nyt studie sammenligner BTK-hæmmere til behandling af R/R CLL

/ Hæmatologi / Carsten Utoft Niemann

EHA23 Insights into the Changing Landscape of Myeloma Treatments

/ Hæmatologi / Fredrik Schjesvold

Ny behandlingsmulighed for patienter med R/R CLL

/ Hæmatologi / Carsten Utoft Niemann
Se oversigt

Abstracts fra EHA 2022

Ibrutinib keeps on delivering now as first-line treatment for older patients with mantle cell lymphoma

/ Hæmatologi / BestPractice Nordic

Superior safety profile for decitabine vs chemotherapy for older patient with AML

/ Hæmatologi / BestPractice Nordic

A novel CAR-T cell therapy thas proven highly effective for patients with RRMM

/ Hæmatologi / BestPractice Nordic

A new phase 3 trial shows significantly prolonged overall survival for patients with AML

/ Hæmatologi / BestPractice Nordic

Improved PFS is achievable using targeted therapy combinations with venetoclax in fit patients with treatment naïve CLL 

/ Hæmatologi / BestPractice Nordic

Treatment of Burkitt lymphoma with DA-EPOCH-R is associated with significant less infectious complications, transfusions, and hospitalization days 

  • / BestPractice Nordic

Se highlights EHA webinar 2022

Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video
Martin Hutchings

To bispecifikke antistoffer er på vej mod godkendelse mod diffust storcellet B-celle lymfom

/ Martin Hutchings
Lymfom Play the Video
Carsten Utoft Niemann

Tidsbegrænset venetoclax-baseret kombinationsbehandling opnår bedre PFS og MRD-negativitet ved behandling af CLL

/ Carsten Utoft Niemann
CLL Play the Video
Martin Hutchings

Hidtil højeste overall survival udfordrer 1.-linjebehandling ved Hodgkin lymfom

/ Martin Hutchings
Lymfom Play the Video

Gå ikke glip af det nyeste fra Hæmatologi

Skriv dig på og få nye artikler, MEDtalks og magasiner i din indbakke

Send mig seneste nyt fra hæmatologi

Mere fra EHA 2022

Daniel Kristensen

Tillæg af andengenerations-FLT3-inhibitor til intensiv kemoterapi og konsolidering hos voksne med AML

/ Daniel Kristensen
EHA22AML Play the Video
Agoston Gyula Szabo

Værdien af højdosisbehandling som tillæg til Rvd induktion og konsolidering ved myelomatose

/ Agoston Gyula Szabo
EHA22Myelomatose Play the Video
Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video

Mere fra EHA 2021

Paolo Strati

Phase 1 Results in SIRPα Antibody CC-95251 in Combination with Rituximab in Patients with R/R NHL

/ Paolo Strati
EHA22Lymfom Play the Video
Kirsten Grønbæk

Hvad har GDPR betydet for den nordiske forskningsscene? Vigtigste take-aways fra EHA med Kirsten Grønbæk

/ Kirsten Grønbæk
EHA22 Play the Video
Othman Al-sawaf

CLL14 study five-year results: Significantly superior efficacy for Ven-Obi

/ Othman Al-sawaf
EHA22CLL Play the Video
Daniel Kristensen

Nyt landsdækkende studie stiller spørgsmålstegn ved betydningen af dosisreduktion hos overvægtige AML-patienter

/ Daniel Kristensen
EHA22AML Play the Video
Jean-Marie Michot

Novel oral agent with promising result as second-line treatment option for patients with T-Cell Lymphoma

/ Jean-Marie Michot
EHA22Lymfom Play the Video
Paul Richardson

A new randomized study suggests an improved depth of response and PFS for patients relapsing on Lenalidomide

/ Paul G. Richardson
EHA22Myelomatose Play the Video
Læs mere
Arnon Kater

The main clinical message from the Five-Year Analysis of Murano Study

/ Arnon P. Kater
EHA22CLL Play the Video
Paul Richardson

Longer PFS and higher ORR for frailty patients with R/R Multiple Myeloma treated with PVd than Vd

/ Paul G. Richardson
EHA22Myelomatose Play the Video
Jakob Nordberg Nørgaard

A new study shows that PTCD and MRD are complementary and necessary for doing a whole assessment on patient-response for myeloma patients

/ Jakob Nordberg Nørgaard
EHA22Myelomatose Play the Video
Back to top